Subgroup analyses from an international, doubleblind, randomised, phase 3 trial evaluating the effect of denosumab on bone metastasis-free survival in men with castrate-resistant prostate cancer
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Data de publicación
2011Título da revista
Asia-Pacific Journal of Clinical Oncology
Tipo de contido
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)